Impact of reproduction number on multiwave spreading dynamics of COVID-19 with temporary immunity : a mathematical model

B Shayak[1], Mohit M Sharma[2*], Manas Gaur[3] and Anand Kumar Mishra[4]

[1] Theoretical and Applied Mechanics, Mechanical and Aerospace Engineering, Cornell University, Ithaca – 14853, New York State, USA

[2] Weill Cornell Medicine, 1300 York Avenue, New York City – 10065, New York State, USA

[3] College of Engineering and Computing, University of South Carolina, Columbia – 29208, South Carolina, USA

[4] Mechanical and Aerospace Engineering, Cornell University, Ithaca – 14853, New York State, USA

* Corresponding author. Email : mos4004@med.cornell.edu

Tuesday 10 November 2020

Keywords. COVID-19 reinfection   SEIRS-type delay model   Simple and complex immune response   Multiple wave solutions

Highlights.

- We show a subtle interplay between public health measures and immune response.

- We account for different durations of sterilizing and severity-reducing immunity.

- Our results prepare us for what might happen with large-scale temporary immunity.

- Our model is relevant for predicting disease dynamics after a vaccine is invented.

Word counts. Abstract – 196, Text only – 3483, Manuscript total – 5377, Supplementary material – 2733, Submission total – 8110

ABSTRACT

Objectives: The recent discoveries of phylogenetically confirmed COVID-19 reinfection

cases worldwide, together with studies suggesting that antibody titres decrease over time,

raise the question of what course the epidemic trajectories may take if immunity were really

to be temporary in a significant fraction of the population. The objective of this study is to

answer this question.

Methods: We construct a ground-up delay differential equation model tailored to incorporate

different kinds of immune response. We consider two immune responses here : (*a*) short-

lived immunity of all kinds, and (*b*) short-lived sterilizing immunity with durable severity-

reducing immunity.

Results: Multiple wave solutions to the model are manifest for intermediate values of the

reproduction number *R*; interestingly, for sufficiently low as well as sufficiently high *R*, we

find conventional single-wave solutions despite the temporary immunity.

Conclusions: The versatility of our model and its very modest demands on computational

resources ensure that a set of disease trajectories can be computed virtually on the same day

that a new and relevant immune response study is released. Our work can also be used to

analyse the disease dynamics after a vaccine is certified for use and information regarding its

immune response becomes available.

Introduction

Between 24th August and today, nine phylogenetically confirmed cases of COVID-19 reinfection have been discovered worldwide – the first in Hong Kong (To et. al. 2020), two more in Greater Noida, India (Sinha, Gupta et. al. 2020), two in Belgium (van Elslande et. al., Selhorst et. al. 2020), two in USA (Goldman et. al., Tillett et. al. 2020), one in Ecuador (CGTN 2020) and one in the Netherlands (Mulder et. al. 2020). In eight of these cases, the patients were presumed immunocompetent; among these, the second infections were milder than the first in six cases and more severe in two. Much about the immune response to SARS-CoV-2 is currently unknown. Edridge et. al. (2020) have found that immunity against infection by benign coronaviruses (not SARS-CoV, MERS-CoV or SARS-CoV-2!) lasts for a few months and reinfection is common from one year onwards. Wajnberg et. al (2020), at Mount Sinai Hospital in New York, USA found that among a cohort of almost 20,000 patients, all but one demonstrated significant antibody titre levels in blood plasma at three months following the original infection. Siddiqui et. al. (2020) corroborated these results via a smaller study conducted at Max Hospital, New Delhi, India.

An observational cohort study (Crawford et. al. 2020) on 34 patients conducted at the University of Washington at Seattle found that over a 3- to 5-month period, antibody concentrations decreased over time, in a manner consistent with the immune responses to acute infections by other viruses including influenza, SARS and MERS. In these infections, the initial decrease in titres is followed by a plateau; whether this is true of SARS-CoV-2 is unknown as of now. Abu-Raddad et. al. (2020) have reported that out of more than 1,30,000 patients in Doha, Qatar infected with COVID-19, 243 persons reported a positive swab 45 or more days after the original positive test; 54 out of these 243 had "strong or good evidence for reinfection". All the reinfections were asymptomatic or presented mild symptoms on the second bout; however the initial symptom profile of these patients had been mild or

asymptomatic as well. Kowitdamrong et. al. (2020) report upto 20 percent post-infection

seroconversion failure rate in mild or asymptomatic patients in Thailand – they do not

document any reinfection cases. Lumley et. al. (2020) have very recently reported an

antibody half-life of 85 days and a median time of 137 days to loss of positivity; these results

are corrborated by Robertson et. al. (2020). A few potential cases of reinfection have also

been reported in media for some time before the first documented case – in these instances,

the evidence is not fully credible (McCamon, Saplakoglu, Ackerly 2020) .

Two systematic reviews deal with the antibody response (Post et. al. 2020) and the cellular

immune response (Shrotri et. al. 2020) to the virus. The former contains amplification of the

kind of results we discussed above; the latter states that the response of T-cells to SARS-

CoV-2 is currently unknown. Lavine et. al. (2020) propose that the immune response to the

virus will determine the manner of transition of COVID-19 to endemicity; in the absence of

known facts, this work is predominantly speculative at this time. Recent cross-sectional

studies from Paris (Anna et. al. 2020) and London (Ward et. al. 2020) find decreasing

seroprevalence as a function of time; this may be related to decreasing titre levels and might

indicate a possibility of reinfection. In two recent, reassuring developments, Zuo et. al. (2020)

in Manchester, UK and Ogega et. al. (2020) in Baltimore, USA have found significant levels

of T- respectively B-cells in recovered patients at 25 respectively 15 weeks following

infection; both studies included mild or asymptomatic patients as well as patients with very

low antibody titre levels. This indicates that durable cellular immunity may be present against

this virus even if antibodies decay over time.

Although the reinfection cases so far are isolated, the almost daily updates on the immune

response to SARS-CoV-2 make us wonder what the epidemiological consequences might be

if the immunity duration indeed turns out to be finite for a significant fraction of the

population. The only approach which can allow inroads into this question is mathematical

modeling. Giordano et. al. (2020) and Bjornstad et. al. (2020) account for the possibility of

reinfection, with the latter finding an oscillatory approach towards the eventual endemic

equilibrium. Kosinski (2020) however finds multiple waves of COVID-19 if the immunity

duration is finite. Sandmann et. al. (2020), in an analysis of this situation in the context of a

vaccine, find smooth oscillations about an endemic equilibrium, which change to jerky

oscillations with periodic lockdown. In this Article, we show that the case trajectories with

temporary immunity actually depend in an intricate manner on the reproduction number R.

Before commencing our analysis, we clarify that we are currently treating large-scale

temporary immunity as a hypothetical, hopefully worst-case scenario, regarding the validity

of which we do not yet have sufficient available data. Also, in this work, we do not attempt to

model the effects of vaccination; all the possibilities that might come into play after

introduction of this new variable will be considered in a subsequent analysis.

Methods

We start from a delay differential equation (DDE) model constructed by our group (Shayak

et. al. 2020, Mohit and Shayak 2020, hereinafter referred to as "References [26,27]"), which

accounts for many realistic features associated with COVID-19 transmission. This model can

be easily adapted to accommodate a given immune response. The dependent variable $y(t)$

denotes the cumulative number of corona cases in the region of interest (typically a town,

neighbourhood, village or other area with good interaction among the inhabitants) as a

function of time, measured in days. The parameters in the model are:

• m_0 : the per-case spreading rate which accounts for factors such as the degree of

mobility (i.e. lockdown/unlock), extent of mask use, extent of handwashing and other

public health measures

• τ_1 : the asymptomatic transmission period which we take to be 7 days throughout

• τ_2 : the pre-symptomatic transmission period which we take to be 3 days throughout

• μ_1 : the fraction of patients who are asymptomatic ($0<\mu_1<1$)

• μ_3 : the fraction of patients (both symptomatic and asymptomatic) who are NOT

detected in contact tracing drives and quarantined ($0<\mu_3<1$)

• N : the total number of susceptible people in the region at the start of the epidemic

In References [26,27], we had assumed that one bout of infection renders everlasting

immunity (practically, immunity lasting longer than the epidemic's progression). Now, we

account for two different kinds of immune response, as follows.

• Simple response: In this scenario, one bout of infection renders a person insusceptible

to fresh infection for a time τ_0 days (τ_0 much greater than τ_1 and τ_2) following

recovery, after which s/he again turns susceptible to the disease in its original form.

• Complex response: In this scenario, adapted from Lavine et. al. (2020), a person is

initially susceptible to the current, highly virulent form of the disease. The first bout

of infection renders him/her completely insusceptible for τ_0 days following recovery,

after which s/he turns susceptible to a lower virulence form of the disease. If infected

the second time, then s/he becomes permanently insusceptible to further infection.

As is customary in lumped parameter or compartmental models, the value of τ_0 used in the

model must be an average over the entire population. The experiences of the first few

confirmed reinfections may well indicate a general trend favouring the second immune

response to the first; in the absence of data, we shall work with both assumptions.

It can be shown (Section 2 of the Supplementary Material) that with the simple immune

response, the dynamics of the disease is governed by the DDE

$$139 \qquad \frac{\mathrm{d}y}{\mathrm{d}t} = m_0 \left[1 - \frac{y(t) - y(t - \tau_0)}{N} \right] \left[\begin{array}{l} y(t) - \left(1 - \mu_3 \right) y(t - \tau_2 / 2) \\ - \left(1 - \mu_1 \right) \mu_3 y(t - \tau_2) - \mu_1 \mu_3 y(t - \tau_1) \end{array} \right] \quad . \quad (1)$$

140 With the complex immune response, we need two dependent variables : $y(t)$, the cumulative

141 number of cases of the high virulence form and $z(t)$, the cumulative number of cases of the

142 lower virulence form. We let μ_{1a} and μ_{1b} (presumably greater than μ_{1a}) be the asymptomatic

143 fractions for the two forms and keep all other parameters identical for both. Then, the

144 dynamics of y and z are governed by the following coupled system of DDEs

$$145 \qquad \frac{\mathrm{d}y}{\mathrm{d}t} = m_0 \left[1 - \frac{y(t)}{N} \right] \left[\begin{array}{l} y(t) - \left(1 - \mu_3 \right) y(t - \tau_2 / 2) - \left(1 - \mu_{1a} \right) \mu_3 y(t - \tau_2) - \mu_{1a} \mu_3 y(t - \tau_1) \\ + z(t) - \left(1 - \mu_3 \right) z(t - \tau_2 / 2) - \left(1 - \mu_{1b} \right) \mu_3 z(t - \tau_2) - \mu_{1b} \mu_3 z(t - \tau_1) \end{array} \right]$$

146 $\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad$, (2a)

$$147 \qquad \frac{\mathrm{d}z}{\mathrm{d}t} = m_0 \left[\frac{y(t - \tau_0) - z}{N} \right] \left[\begin{array}{l} y(t) - \left(1 - \mu_3 \right) y(t - \tau_2 / 2) - \left(1 - \mu_{1a} \right) \mu_3 y(t - \tau_2) - \mu_{1a} \mu_3 y(t - \tau_1) \\ + z(t) - \left(1 - \mu_3 \right) z(t - \tau_2 / 2) - \left(1 - \mu_{1b} \right) \mu_3 z(t - \tau_2) - \mu_{1b} \mu_3 z(t - \tau_1) \end{array} \right]$$

$\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad$, (2b)

whose derivation is again given in the Supplementary Material, Section 2.

For both models, we present the solutions in a Notional City having an initial susceptible

population of N=3,00,000 (the epidemic durations and case trajectory shapes are almost

independent of N and the case counts scale as N for large N) and 80 percent asymptomatic

carriers i.e. μ_1=0·8 (or μ_{1a}=0·8 if appropriate) in the current, high virulence form of the

disease. We let μ_{1b}=0·95 for the lower virulence form and take the immunity duration τ_0 to be

200 days. We solve the equations numerically in Matlab using 2nd order Runge Kutta method

with step size 0·001 day. The initial condition function we take is zero cases for the first 193

days followed by linear growth of cases at 100 cases/day for the next seven days (with the

complex immune response, this growth refers to the high virulence cases – the lower

virulence cases remain zero). We take $t=0$ to be the 194th day of the initial condition period.

One issue needs special mention – in a numerical simulation, the case rate will never be

identically zero but will be something like $0 \cdot 001$ cases/day (or machine epsilon cases/day).

This can pose a serious problem in a situation where there are potential second waves of the

epidemic. To circumvent this issue, we have arranged for manual termination of the run if the

case rate becomes sufficiently low. Defining the number of active cases at time t to be

$y(t)-y(t-14)$, we stop the run if there is less than one active case for 14 consecutive days.

While the number 14 (twice) may be somewhat arbitrary, the criterion of a low enough active

case count for a long enough period is a very reasonable indicator of the true end of the

outbreak. We run all simulations either upto $t=1400$ days or until they terminate, whichever is

earlier.

Results

All results in this Section are based on an assumed immunity period of 200 days. The exact

value is not of the greatest significance; as we shall see, the important thing is whether this

period is shorter or longer than the evolution of the outbreak with permanent immunity. Six

different solution classes corresponding to different parameter values – labelled as Notional

Cities A through F – of the model with permanent immunity have been derived in References

[26,27] and recapitulated in Section 1 of the Supplementary Material. We shall consider the

same Cities in the present analysis.

Scenario 1 : Simple immune response

We first consider the simple immune response, modelled by (1). Notional City A has

$m_0=0\cdot23$ and $\mu_3=0.5$, which, with permanent immunity, resulted in the epidemic's being

driven monotonically to containment in 120 days. With the simple immune response, the

time-trace of the disease is shown in Figure 1 below. Here and henceforth, we show three

things in the same plot : $y(t)$ as a blue line, its derivative as a green line and the "epi-curve" or

weekly increments in cases scaled down by a factor of 7, in grey bars.

Figure 1: *City A eliminates the epidemic via non-pharmaceutical interventions alone.*

The response remains the same as it was with permanent immunity. Next, we present City C,

which has $\mu_3=3/4$ and $m_0=0\cdot5$ all the time. (We use $0\cdot23$ for a "low" value of m_0 since we

obtained it from data fits in References [26,27]; the chosen "high" value of $m_0=0\cdot5$ generates

90 percent infection level at the end of the outbreak.) With the simple immune response, the

trajectory is shown in Figure 2 below.

Figure 2: *City C reaches herd immunity well before the 200-day mark. 'k' denotes thousand and 'L'*

hundred thousand.

Once again, there is no change in behaviour from the permanent immunity case. City B has

$m_0=0{\cdot}23$ like City A but $\mu_3=3/4$ like City C. With permanent immunity, City B crawls up to

about 26 percent infection level over a period of 220 days. Here however, the 220-day run

becomes longer than the assumed immunity duration of 200 days, and the result, now labelled

as City B1, is shown in Figure 3.

Figure 3: *City B1 (we shall use B2 to denote the same city with complex immune response) is a less*

effective form of A and has multiple waves of COVID-19. 'k' denotes thousand and 'L' hundred

thousand. We have stopped the simulation at 1400 days – the waves persist after that time as well.

We can see wave after wave of outbreaks here. While we do not believe that the disease can

really run unmitigated for four years, the long simulation runtime shows the perfect

periodicity of the case trajectories. The case count at the end of the run is greater than the

city's initial susceptible population, so at least some people have been infected at least twice.

Cities D and E of References [26,27] were similar to C and A respectively and again, they do

not show any change when the new immune response is incorporated. City F, which

demonstrates reopening-induced second waves, is more interesting. We start off this City

with the parameter values of B, on a path to multiple waves. One hundred and fifty days into

the outbreak it reopens completely, raising m_0 to 0·5, aiming to infect its entire population

before immunity runs out. The result is shown in Figure 4.

Figure 4: *City F is bold and "beats the virus to the finish line". 'k' denotes thousand and 'L' hundred*

thousand.

Howsoever controversial this strategy might appear, it works. The reopening generates an

immediate second wave but it does succeed in making the epidemic vanish completely at 210

days and 2,46,000 infections. This strategy however has an unhappy variant. City G, instead

of reopening at one shot, increases m_0 linearly from $0 \cdot 23$ to $0 \cdot 50$ over the interval from 150 to

250 days. The resulting infection profile is shown in Figure 5.

Figure 5: *City G1 is F gone wrong, and the error carries a price. 'k' denotes thousand and 'L'*

hundred thousand.

There are three separate waves of infections here, each more severe than the first, and the

cumulative case count exceeds 150 percent of the total population.

Scenario 2 : Complex immune response

We now consider the complex immune response, modelled by (2). Numerical work confirms

our expectation that Cities A, C and F will show no difference from the simple immune

response case since the epidemic terminates before the immunity duration lapses. We focus

on City B, now renamed to B2. For this plot, the colour legend will be y in blue, $\dot{y}$ in green, z

in red, $\dot{z}$ in magenta and the epi-curves in grey for y and cyan for z. The results are in Figure

6.

Figure 6 : *City B with complex immune response. 'k' denotes thousand and 'L' hundred thousand.*

W/7 denotes the weekly increments in cases scaled down by 7 as previously, while HVF and LVF refer

to the high and lower virulence forms of the disease respectively.

Again there are multiple waves, but this time they are progressively attenuated so that the

total fraction of the high virulence infection remains less than 60 percent. An equally

significant difference between the two immune responses occurs with City G, Figure 7

below.

Figure 7: *City G with complex immune response. In the right third of the plot, the cyan bars obscure*

the smaller grey bars; the latter are enveloped by the green curve which is still visible. 'k' denotes

thousand and 'L' hundred thousand. W/7 denotes the weekly increments in cases scaled down by 7 as

previously, while HVF and LVF refer to the high and lower virulence forms of the disease

respectively.

The massive third wave of G1 now occurs almost entirely in the lower virulence form.

Discussion

The difference between the cities A, B and C lies in their reproduction number R, which is

proportional to m_0 if other parameters are held constant. City A has the starting value

$R_0=0\cdot886$, City B has $R_0=1\cdot16$, and City C has $R_0=2\cdot5$. With permanent immunity, a low but

greater-than-unity R_0 leads to a long epidemic duration with a lower caseload, while high R_0

leads to a shorter duration with a higher caseload. The latter carries a significant risk of

overwhelming healthcare facilities and causing unnecessary deaths. With temporary

immunity however, we see multiple waves of disease if the cutoff interval τ_0 becomes less

than the evolution time with permanent immunity (Supplement, Section 3 contains some

pedagogical examples that motivate these findings).

In this example, we took τ_0 to be 200 days, which is towards the longer end of the free

evolution duration with time-independent parameters (with time-dependent parameters like

periodic lockdown, the epidemic durations can become much longer). Hence we see the wave

solutions in a small region of parameter space – we find that with the simple immune

response, for all parameters except m_0 being held to their City B values, a containment (City

A) solution for low m_0 gives way to a multiple wave (City B1) solution as m_0 is increased

above 0·20, while that cedes to a one-shot logistic-like (City C) solution at m_0=0·25 and

higher. A shorter immunity duration would have caused multiple waves over a larger range of

m_0. In our example, the waves are close to sinusoidal near m_0=0·20; as m_0 is increased, the

crests get higher and narrower and the troughs lower and wider. From a public health

perspective, a low and wide trough might be an opportunity to intensify test-trace-treat efforts

and stamp the disease out. With the complex immune response, the total numbers of cases are

bounded by 3,00,000 infections of both y and z. Hence, the infinitely periodic waves are no

longer possible – they keep attenuating in size before the epidemic terminates outright. In

both Cities B and G, the time interval between successive waves appears to be in the range

1·5τ_0 to 2τ_0. Cities F and G show the possible scenarios with reopening. In Table 1, we

summarize the different case trajectories possible for different values of R with three kinds of

immune response – permanent, simple and complex.

Value of R	Example Notional City	Permanent Immunity	Immune response 1	Immune response 2
$R<1$ throughout	A	Containment of epidemic in time		
Constant intervention level; $R_0>1$ but not too high	B	Slow growth of cases, long epidemic duration	Slow growth of cases, infinite waves of epidemic	Slow growth of cases, two to three attenuating waves
Constant intervention level; R_0 very high	C	Entire population infected rapidly		
Abrupt increase in R after a time interval	F	Two waves of disease with high case counts and rates in the second		
Gradual increase in R after a time interval	G	Two waves of disease with high case counts and rates in the second	Three waves of disease with progressively increasing counts and rates	Three waves of disease but third (most severe) wave in lower virulence form

Table 1 : *Different scenarios possible with different levels of intervention combined with different*

kinds of immune response.

We note that the second waves seen after relaxing public health interventions are

fundamentally different from the second and subsequent waves exhibited under the aegis of

temporary immunity. The former is caused by more susceptible people getting exposed and

infected, as in the second wave of City F, while the latter is caused by recovered cases

turning re-susceptible and thus increasing the size of the susceptible pool, like the waves in

City B1. The waves in City G1 are of both types, with the second wave being of the former

type and the third of the latter. This is why in City G2 (Figure 7), where previously infected

people suffer a "different" disease, the second wave occurs primarily in the high virulence

form while the third occurs in the lower virulence form. The phenomenon we are currently

seeing in European countries and elsewhere is overwhelmingly the result of weakening of

public health intervention measures and not of immunity having run out. We are unsure as to

what factors governed the successive waves of the deadly 1918-9 influenza pandemic and

how that disease eventually ended.

Briefly revisiting the prior Literature, we find that some prior works (Giordano et. al.,

Bjornstad et. al. 2020, Cooke et. al. 1996, Travicki 2017, Kiran et. al. 2020) appear to have

missed the multiple wave solutions possible with temporary immunity. While Kosinski

(2020) and Sandmann et. al. (2020) do find these waves, they do not obtain the diverse

possible epidemic trajectories depending on R. Since R is governed by public health

interventions, our analysis reveals a subtle interconnection between immunity and public

health, which together influence the fate of the pandemic. In Section 3 of the Supplementary

Material, we have explained why we find the present results to be more realistic. Finally, we

have never seen an S-E-I-R framework being used to model a situation such as the complex

immune response where a person can be infected exactly twice but not more.

Some of the limitations of the present study are the natural constraints associated with any

compartmental or lumped parameter model. For example, the immunity duration used in the

model has to be an average over the entire population, which can be refined to some degree

by introducing age- or vulnerability-structuring (Sandmann et. al. op. cit). When there are

very few cases in a region, the lumped parameter model will no longer be valid. The actual

end of the outbreak will be determined by the testing, tracing and treatment of each individual

case. Another limitation arises from the current lack of knowledge regarding the human

immune response to the new pathogen SARS-CoV-2. Here we have assumed two (plausible)

kinds of response, one where immunity completely lapses after a given timeframe and the

second where severity-reducing immunity persists indefinitely. Future work may reveal the

actual immune response to be more complex than either of these assumptions. Moreover, at

least six strains of SARS-CoV-2 have been identified to date (Mercatelli et. al. 2020). At

present, we know little about the spreading dynamics of individual strains (Zhang et. al.

2020) and still less about the degree of cross-immunity provided by one strain against

another.

In this variability however also lies our model's primary strength. The model structure makes

it easy to incorporate any kind of immune response (Shayak and Mohit 2020). The

computational requirement is negligible, with the run for each Notional City taking about one

second on a personal computer. Yet, the model is quite powerful since it can generate diverse

classes of solutions which are beyond the scope of other models. This means that the moment

more information regarding the immune response becomes known, the new information can

be encoded into the model framework and accurate case trajectories predicted forthwith. Our

analysis will also be of considerable value in calculating the epidemic dynamics after a

vaccine is released and mass vaccination is initiated. We shall wait for such an analysis until

a vaccine release is imminent or confirmed, since, by that time much more information

regarding the immune response to infection and vaccination will be fact instead of

speculation.

338   ---- o ----

Acknowledgement

340   We would like to thank the anonymous reviewer for valuable suggestions which have

341   resulted in substantial improvement to the quality of the presentation.

Funding statement

343   We have NO funding to report for this study.

Conflict of interest statement

345   We have NO conflict of interest.

Data Availability Statement

347   This Article does not use or feature any data.

References

Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E,

et al. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting.

MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.08.24.20179457v1.

Ackerly DC. My patient caught Covid-19 twice. So long to herd immunity hopes?

Vox 2020. available at : https://www.vox.com/2020/7/12/21321653/getting-covid-19-twice-

reinfection-antibody-herd-immunity.

Anna F, Goyard S, Lalanne AI, Nevo F, Gransagne M, Souque P, et al. High

seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. MedRxiv

2020. available at https://www.medrxiv.org/content/10.1101/2020.10.25.20219030v1.

Bjørnstad O, Shea K, Krzywinski M, Altman N. The SEIRS model for infectious

disease dynamics. Nature Methods 2020;17 (6) : 557-8.

CGTN. Ecuador confirms first case of COVID-19 reinfection. Available from:

https://news.cgtn.com/news/2020-08-30/Ecuador-confirms-first-case-of-COVID-19-

reinfection-Tn8RnpNU40/index.html.

Cooke KL, Van Den Driessche P. Analysis of an SEIRS epidemic model with two

delays. Journal of Mathematical Biology 1996; 35 (2) : 240-60.

Crawford KH, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics

of neutralizing antibody titers in the months after SARS-CoV-2 infection. MedRxiv 2020.

available at https://www.medrxiv.org/content/10.1101/2020.08.06.20169367v1.

Edridge AWD, Kaczorowska JM, Hoste AC, Bakker M, Klein M, Jebbink MF, et al.

Human coronavirus reinfection dynamics: lessons for SARS-CoV-2. MedRxiv 2020.

available at https://www.medrxiv.org/content/10.1101/2020.05.11.20086439v2.

Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. A

SIDARTHE model of COVID-19 epidemic in Italy. arXiv preprint 2020. article number

2003.09861

Goldman J, Wang K, Röltgen K, Nielsen S, Roach J, Naccache S, et al. Reinfection

with SARS-CoV-2 and Failure of Humoral Immunity: a case report. Medrxiv 2020. available

at https://www.medrxiv.org/content/10.1101/2020.09.22.20192443v1.

Gupta V, Bhoyar RC, Jain A, Srivastava S, Upadhayay R, Imran M, et al.

Asymptomatic reinfection in two healthcare workers from India with genetically distinct

SARS-CoV-2. Clinical Infectious Diseases 2020. online ahead of print.

Kiran R, Roy M, Abbas S, Taraphder A. Effect of population migration and

punctuated lockdown on the spread of SARS-CoV-2. arXiv preprint 2020. article number

2006.15010.

Kosinski RJ. The Influence of time-limited immunity on a COVID-19 epidemic: a

simulation study. MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.06.28.20142141v1.

Kowitdamrong E, Puthanakit T, Jantarabenjakul W, Prompetchara E,

Suchartlikitwong P, Putcharoen O, et al. Antibody Responses to SARS-CoV-2 in

Coronavirus Diseases 2019 Patients with Different Severity. MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.09.06.20189480v1.

Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the

changing severity of COVID-19 during the transition to endemicity. MedRxiv 2020.

available at https://www.medrxiv.org/content/10.1101/2020.09.03.20187856v1.

Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC et. al., "The Duration,

dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare

workers," MedRxiv Article (2020) available at

https://www.medrxiv.org/content/10.1101/2020.11.02.20224824v1

McCamon S. USS Roosevelt Sailors Test Positive For COVID-19. Again. NPR

Media Article 2020. available at https://www.npr.org/sections/coronavirus-live-

updates/2020/05/16/857379338/5-uss-roosevelt-sailors-test-positive-for-covid-19-again.

Mercatelli D, Giorgi FM. Geographic and Genomic Distribution of SARS-CoV-2

Mutations. Frontiers in Microbiology 2020; 11 : 1800.

Mulder M, van der Vegt DSJM, Munnink BBO, van Kessel CHG, van de Bovenkamp

J et. al., "Reinfection of SARS-CoV-2 in an immunocompromised patient," Clinical

Infectious Diseases 2020; online ahead of print.

Ogega CO, Skinner NE, Blair PW, Park H-S, Littlefield K, Ganesan A, et al. Durable

SARS-CoV-2 B cell immunity after mild or severe disease. MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.10.28.20220996v1.

Post N, Eddy D, Huntley C, van Schalkwyk MC, Shrotri M, Leeman D, et al.

Antibody response to SARS-CoV-2 infection in humans: a systematic review. MedRxiv

2020. available at https://www.medrxiv.org/content/10.1101/2020.08.25.20178806v1.

Robertson LJ, Moore JS, Blighe K, Ng KY, Quinn N, Jennings F, et al. SARS-CoV-2

antibody testing in a UK population: detectable IgG for up to 20 weeks post infection.

MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1.

Sandmann F, Davies N, Vassall A, Edmunds WJ, Jit M. The potential health and

economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK:

transmission model-based future scenario analysis and economic evaluation. MedRxiv 2020.

available at https://www.medrxiv.org/content/10.1101/2020.09.24.20200857v1.

Saplakoglu Y. Recovered patients who tested positive for COVID-19 likely not

reinfected. Live Science 2020. available at : https://www.livescience.com/coronavirus-

reinfections-were-false-positives.html.

Selhorst P, van Ierssel S, Michaels J, Marien J, Bartholomeeusen K et. al.,

"Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial

outbreak despite primary neutralizing antibody response," MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.11.05.20225052v1.

Sharma MM, Shayak B. Public Health Implications of a delay differential equation

model for COVID 19. KIML Workshop Proceedings; KDD2020. available at

https://aiisc.ai/KiML2020/papers/KiML2020_paper_7.pdf.

Shayak B, Sharma MM, Gaur M. A New delay differential equation model for

COVID-19. KIML Workshop Proceedings; KDD2020. available at

https://aiisc.ai/KiML2020/papers/KiML2020_paper_6.pdf.

Shayak B and Sharma MM, "A New approach to the dynamic modeling of an

infectious disease," MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.10.30.20223305v1.

Shrotri M, van Schalkwyk MC, Post N, Eddy D, Huntley C, Leeman D, et al. Cellular

immune response to SARS-CoV-2 infection in humans: a systematic review. MedRxiv 2020.

available at https://www.medrxiv.org/content/10.1101/2020.08.24.20180679v1.

Siddiqui S, Naushin S, Pradhan S, Misra A, Tyagi A, Looma M, et al. SARS-CoV-2

antibody seroprevalence and stability in a tertiary care hospital-setting. MedRxiv 2020.

available at https://www.medrxiv.org/content/10.1101/2020.09.02.20186486v1.

Sinha M. First confirmed Covid reinfection: Have no symptoms, I feel normal, says

GIMS nurse. Times of Inida 2020. available at :

https://timesofindia.indiatimes.com/city/noida/first-confirmed-covid-reinfection-have-no-

symptoms-i-feel-normal-says-gims-nurse/articleshow/78156844.cms.

Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al.

Genomic evidence for reinfection with SARS-CoV-2: a case study. The Lancet Infectious

Diseases 2020. online ahead of print.

To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. COVID-19 re-

infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole

genome sequencing. Clinical Infectious Diseases 2020. online ahead of print.

Trawicki MB. Deterministic Seirs Epidemic Model for Modeling Vital Dynamics,

Vaccinations, and Temporary Immunity. MDPI Journal of Mathematics 2017; 5 (1): 7.

Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen

B, Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct

strain. Clinical Infectious Diseases 2020. online ahead of print.

Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, et al. SARS-

CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least

three months. MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1.

Ward H, Cooke G, Atchison CJ, Whitaker M, Elliott J, Moshe M, et al. Declining

prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults.

MedRxiv 2020. available at

https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.

Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, et al. The D614G

mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.

BioRxiv 2020. available at https://www.biorxiv.org/content/10.1101/2020.06.12.148726v1.

Zuo J, Dowell A, Peirce H, Verma K, Long HM et. al., "Robust SARS-CoV-2

specific T-cell immunity is maintained at 6 months following primary infection," BioRxiv

2020. available at https://www.biorxiv.org/content/10.1101/2020.11.01.362319v1.

SUPPLEMENTARY MATERIAL for "Impact of reproduction number on multiwave spreading dynamics of COVID-19 with temporary immunity : a mathematical model"

by

B Shayak, Mohit M Sharma, Manas Gaur and Anand Kumar Mishra

In this Supplement we cover three topics not included in the article proper. The first is a brief recapitulation of our prior work [S1,S2] where we derive the modeling philosophy and show six different solution classes obtained with permanent immunity rather than temporary. The second is a derivation of the model equations (1) and (2) of the article proper. The third is a logic-based explanation for some of the counter-intuitive solutions we report in the article proper.

1 Recapitulation of our prior study

The philosophy behind the delay differential equation model has been proposed in References [S1] and [S2] of this Supplement (cited as References [26,27] in the article proper). We start by summarizing the model derivation and then present the solution classes obtained in these References. This is necessary because the core contribution of the present article adapts this derivation and starts from the same solution classes.

Derivation

The transmission of COVID-19 arises as a result of interactions between cases at large in society and healthy people. These interactions may be either direct or via objects. It is described by the following "word equation" :

$$
\begin{pmatrix} \text{Rate of emergence} \\ \text{of new cases} \end{pmatrix} = \begin{pmatrix} \text{Spreading rate of} \\ \text{each at large case} \end{pmatrix} \times \begin{pmatrix} \text{Probability of} \\ \text{susceptibility} \end{pmatrix} \times \begin{pmatrix} \text{Number of} \\ \text{at large cases} \end{pmatrix} \ , \ \text{(S0)}
$$

which we intend to represent mathematically.

The first term on the above right hand side (RHS) is itself the product of two quantities : the rate q_0 at which each at large case interacts with other people, and the probability P_0 that an interaction between a case and a susceptible person actually results in a transmission. q_0 is determined by the level of social mobility (lockdown/unlock) and by the degree of physical separation being practised; P_0 depends on whether either or both parties are wearing masks and whether they are washing hands, not touching their face, sanitizing objects etc. Both q_0 and P_0 depend directly on public health interventions, so we can combine them into a single term m_0 which represents this aspect of the disease.

The second term on the RHS of (S0) is the probability that the person with whom the at large case interacts, i.e. a random person in the region, is actually susceptible. For now we consider the case where immunity is permanent. In this case, the probability of a random person's being insusceptible is the total number of recovered cases divided by the total number of

people in the region. The former is approximately y, and the latter is N. The recovery count is actually a little less than y since cases take a finite time to recover. But if the recovery duration is much shorter than the overall epidemic duration, which it is in practice, then we can make the assumption of instantaneous recovery and treat it as y. With this assumption, the probability of a random person's being insusceptible is y/N and the probability of his/her being susceptible is $1-y/N$.

The structure of the third term arises from the following argument : if all cases take a time τ days to recover, and remain at large the whole time, then the number of at large active cases now is exactly the number of people who fell sick between now and τ days back – mathematically, this is expressed as $y(t)-y(t-\tau)$. For a maximally realistic picture, we partion the cases into three classes : contact traced cases, untraced symptomatic cases and untraced asymptomatic cases. By definition of the model parameters, the first class amount to fraction $1-\mu_3$ of the total cases; if the contact tracing starts from freshly reporting symptomatic cases, then the average duration these cases remain at large is $\tau_2/2$ where τ_2 is the transmissible latency period. Untraced symptomatic cases account for fraction $\mu_3(1-\mu_1)$ of the total cases and they remain at large for the latency period τ_2 before manifesting symptoms and going into quarantine. Finally, untraced asymptomatic cases account for fraction $\mu_3\mu_1$ of the total cases and these remain at large for the asymptomatic infection period τ_1. Using the $y(t)-y(t-\tau)$ argument on each class leads to the mathematical form of the third term on the RHS of (S0) as

$$n = \left(1-\mu_3\right)\left(y-y(t-\tau_2/2)\right)+\left((1-\mu_1)\mu_3\right)\left(y-y(t-\tau_2)\right)+\mu_1\mu_3\left(y-y(t-\tau_1)\right) \quad . \quad \text{(S1)}$$

Multiplying all the terms on the RHS of (S0) and simplifying the algebra in (S1), we get

$$\frac{dy}{dt} = m_0\left[1-\frac{y}{N}\right]\left[y(t)-\left(1-\mu_3\right)y(t-\tau_2/2)-\left(1-\mu_1\right)\mu_3 y(t-\tau_2)-\mu_1\mu_3 y(t-\tau_1)\right] \quad , \quad \text{(S2)}$$

which is the retarded logistic equation proposed in References [S1,S2]. For further details regarding the derivation of (S2), including justification of the approximations involved, we must refer to [S1,S2].

Solution classes

Here we present the six solution classes to the model which we have found in [S1,S2], and which form the basis for the solution classes considered in the article proper. For each class, we have run the model in a Notional City of initial susceptible population 3,00,000 as we have done in the article proper. As in there, for each plot we show y in blue, $\dot{y}$ in green and the epidemiological curve as grey bars.

The first solution class, City A, corresponds to elimination of the disease via non-pharmaceutical interventions alone. Reduction of social interactions, masking, contact tracing, testing and similar measures ensure that the reproduction number R is less than unity at the start of the outbreak (we have taken it as $0 \cdot 89$ in this particular example) and remains so throughout. Such situations have occurred in New Zealand and Australia.

Figure S1 : *City A contains the epidemic in time.*

The second solution class, City B, features non-pharmaceutical interventions at a lower level than City A, which ensures that $R_0=1\cdot15$. Initially, the outbreak grows exponentially, but then evolves more slowly and infects less than 30 percent of the population by the time it ends. This class of solution (at least in part) has been seen in many regions of the world, such as the cities of Mumbai in India and Buenos Aires in Argentina.

Figure S2 : *City B has a classical bell-shaped epi-curve.*

The third class, City C, attempts no interventions at all. *R* starts off at above $2\cdot5$ and remains high throughout until herd immunity is attained. There is very high case count in a very short time. This type of solution has not been seen anywhere in the real world since no local or national authority is so negligent as to adopt a do-nothing course of action.

Figure S3 : *City C proceeds quickly to herd immunity.*

The fourth class, City D, shows the effects of a late lockdown. Beginning like City C, this city imposes restrictions at the level of City B when the case count becomes 40,000. The solution combines features of Cities B and C – both the case count and the epidemic duration are intermediate between the two extremes. The first wave of COVID-19 in New York City, USA was of this type.

Figure S4 : *City D combines features of B and C.*

Finally, Cities E and F demonstrate reopening. Both start off like City A and then reopen on the 80th day. City E is a success story where increased mobility is combined with high contact tracing, testing etc to keep $R < 1$ throughout. Such reopenings may have taken place in certain East Asian countries.

Figure 5 : *City E is similar to A despite reopening.*

City F is a failure story where the increased mobility results in *R* exceeding unity and there is a wave of disease after the 80th day. Reopening driven second waves (with the first wave resembling City B rather than A) have been seen in many parts of the world, especially in USA and Western Europe.

Figure S6 : *City F shows reopening gone wrong.*

This completes the recapitulation of our prior study [S1,S2]. We note that our model, and hence the results of Cities A through G, are more appropriate for an individual city or even a neighbourhood rather than an entire country. This is because the model assumes good interaction among the region's inhabitants – this assumption is unlikely to hold for a country as a whole, especially under the present circumstances. Rather, a country is made up of dozens of these A-G type cities and the final curve of cumulative cases for this country will be a superposition of the different infection profiles of these cities. Hence, on a national level, public health officials should not attempt to formulate uniform epidemic policies for the country as a whole. It is not uncommon that a phenomenon observed in one region may not be observed somewhere else.

2 Development of the model

We now use the modeling philosophy outlined above to derive the governing equations presented in the article proper. We briefly recapitulate the two kinds of immune response from the article proper. Simple immune response : After contracting the infection, a person remains insusceptible for τ_0 days following recovery and then becomes susceptible again. Complex immune response : After contracting the infection, a person remains insusceptible for τ_0 days, then becomes susceptible to the lower virulence form and after a second infection becomes permanently immune.

We first consider the simple immune response. In the structure (S0), immune response is modelled by the second term on the RHS, so that is the only term which will be different from (S2). The immunity threshold of τ_0 means that at any given instant, the people who are immune are all those who have contracted the infection during the last τ_0 days, and no one else. Hence, the number of insusceptibles at time t is exactly the number of new infections which have occurred between time $t-\tau_0$ and t, which is $y(t)-y(t-\tau_0)$. In proposing this structure, we have retained the approximation of instantaneous recovery and also have ignored deaths. Since the mortality rate of COVID-19 is fortunately quite low, this second assumption is reasonable as well. So the probability that at time t, a random person is insusceptible is $[y-y(t-\tau_0)]/N$, and the probability that s/he is susceptible is its complement,

$$P = 1 - \frac{y(t) - y(t - \tau_0)}{N} \quad . \quad \text{(S3)}$$

Using this in (S0) immediately gives

$$\frac{dy}{dt} = m_0 \left[1 - \frac{y(t) - y(t - \tau_0)}{N} \right] \left[\begin{array}{c} y(t) - \left(1 - \mu_3\right) y(t - \tau_2 / 2) \\ -\left(1 - \mu_1\right) \mu_3 y(t - \tau_2) - \mu_1 \mu_3 y(t - \tau_1) \end{array} \right] \quad , \quad \text{(S4)}$$

which is (1) of the article proper.

With complex immune response, we need to write the structure (S0) for both y and z. The public health term m_0 remains the same for both. In the y-equation, the second term must denote the probability that a random person is susceptible to the high virulence form. As before, let us count the insusceptibles. Any person who has contracted the high virulence form once is insusceptible to it for all future time, so the number of insusceptibles is y and the probability of susceptibility is $1-y/N$. For the third term, we need the total numbers of active and at large y as well as z, which is (S1) written out for both y and z. Thus, we get

$$\frac{dy}{dt} = m_0 \left[1 - \frac{y(t)}{N} \right] \left[\begin{array}{c} y(t) - \left(1 - \mu_3\right) y(t - \tau_2 / 2) - \left(1 - \mu_{1a}\right) \mu_3 y(t - \tau_2) - \mu_{1a} \mu_3 y(t - \tau_1) \\ +z(t) - \left(1 - \mu_3\right) z(t - \tau_2 / 2) - \left(1 - \mu_{1b}\right) \mu_3 z(t - \tau_2) - \mu_{1b} \mu_3 z(t - \tau_1) \end{array} \right] ,$$

$$\text{(S5)}$$

which is (2a) of the article proper.

For the z equation, the per-case spreading rate as well as the number of spreaders remain unchanged; the only thing which changes is the probability that a random person is susceptible to the lower virulence form. At time t, the only people eligible for contracting the lower virulence disease are those who have already contracted the high virulence form once, and that a time τ_0 or more ago. This is the cumulative number of high virulence infections at time $t-\tau_0$, which is $y(t-\tau_0)$. Among these eligible people however, the current count $z(t)$ have

already had the second infection and so must be excluded from the susceptible pool. Thus, the size of the susceptible pool is $y(t-\tau_0)-z(t)$ and the susceptibility probability is

$$P = \frac{y(t-\tau_0) - z(t)}{N} \quad , \quad (S6)$$

leading to the equation

$$\frac{dz}{dt} = m_0 \left[\frac{y(t-\tau_0) - z}{N} \right] \left[\begin{array}{l} y(t) - (1-\mu_3) y(t-\tau_2/2) - (1-\mu_{1a}) \mu_3 y(t-\tau_2) - \mu_{1a}\mu_3 y(t-\tau_1) \\ +z(t) - (1-\mu_3) z(t-\tau_2/2) - (1-\mu_{1b}) \mu_3 z(t-\tau_2) - \mu_{1b}\mu_3 z(t-\tau_1) \end{array} \right]$$

$$, \quad (S7)$$

which is (2b) of the article proper. This completes the derivation of the model.

3 Qualitative motivation and explanation of the solutions

The different solution classes of (1) and (2) we saw in the article proper are quite counter-intuitive so we motivate them here through some pedagogical examples. We had used one such example in an earlier work [S3] to motivate the City A containment solution, which we now recapitulate briefly. This example was the fantasy kingdom of Coronaland where the king declares a 28-day "100 percent lockdown" – literally nobody is allowed to step out of his/her house. Because Coronaland is fictitious, this does not pose a logistical problem of survival. At the end of the lockdown, every case has either recovered or died at home, and the virus does not exist any longer when normal life is restarted. City A of the article proper is the real-world version of Coronaland since the philosophy is the same – with skilful public health measures, the virus is fed new patients at such a small rate that it itself gets annihilated in time.

The pedagogical examples relevant for temporary immunity are the following. The fictitious city of Coronapur (alla Kanpur, Saharanpur) has an initial population of 500 susceptible people, and has zero cases to start with. The duration of immunity is 200 days and every case recovers within a day (consistent with the modeling assumption above). The spread of the virus here is governed by the following simple rule :

- On any day if there are 5 or more than 5 susceptible individuals present, then exactly 5 of them (randomly selected where necessary) contract the virus
- On any day if there are less than 5 susceptible individuals present then all of them contract the virus

We recall that this is a pedagogical example and not a real-world epidemic spreading dynamic ! The case trajectory of Coronapur is simple enough to predict. There are total 5 cases on day 1, 10 on day 2, 15 on day 3 and so on, all the way upto 500 on day 100. Then, since the first batch of cases is still well within its immunity period, there are no more susceptible people left and the propagation stops. On day 100, the last batch of cases also clears the virus which then does not exist in Coronapur any longer. Everyone has been infected but the virus is dead and the epidemic over.

The fantasy city of Coronabad (alla Hyderabad, Allahabad) has everything same as Coronapur except that the number 5 is replaced by 2. The case trajectory starts off with 2 cases on the first day, 4 on the second, 6 on the third, 200 on the 100th (unlike the 500 of Coronapur) and so on upto 400 cases on the 200th day. Thus, on day 201, there are 100 people

who are yet to contract the infection. But, on this day, the cases of day 1 lose their immunity and also get added to the susceptible pool. So the two new infections of day 201 can be anyone from this pool of 102. Similarly on day 202, the two cases from day 201 get removed from the susceptible pool but the two recoveries from day 2 get added and the pool size does not change. This scenario remains invariant for all time – every day there is a susceptible pool of 102 and every day there are 2 new infections from amongst this pool. Even though the initial growth rate is much slower than in Coronapur, the city of Coronabad becomes a land of immortal virus.

The above is exactly what we see in the solutions of (1) and (2). Just as City A is a realistic version of Coronaland, Cities C (also F) and B are realistic versions of Coronapur and Coronabad respectively. A high R as in Cities C and F leads to a fast spreading of the epidemic with high initial case counts but puts the progress of the disease to a stop in time. A lower R (but of course greater than unity) as in City B leads to slower spreading with lower initial case counts but the disease keeps on perpetuating itself. These examples help us to qualitatively understand the solutions and also convince us that our results are a more accurate representation of reality than literature items (indicated in the article proper) which do not find this complex dependence on R.

References

[S1] Shayak B, Sharma MM and Gaur M, "A New delay differential equation for the spread of COVID-19," Proceedings of KiML Workshop, *KDD2020*, available at
https://aiisc.ai/KiML2020/papers/KiML2020_paper_6.pdf
[S2] Sharma MM and Shayak B, "Public health implications of a delay differential equation model for COVID-19," *ibid*. (2020) available at
https://aiisc.ai/KiML2020/papers/KiML2020_paper_7.pdf
[S3] Shayak B and Rand RH, "Self-burnout – a new path to the end of COVID-19," *MedRxiv* Article (2020) available at
https://www.medrxiv.org/content/10.1101/2020.04.17.20069443v2